Cargando…

S100A8, S100A9 and S100A8/A9 heterodimer as novel cachexigenic factors for pancreatic cancer-induced cachexia

BACKGROUND: Cancer cachexia, occurring in ~ 80% pancreatic cancer (PC) patients overall, is a paraneoplastic syndrome mediated by cancer-induced systemic inflammation and characterized by weight loss and skeletal muscle wasting. Identifying clinically relevant PC-derived pro-inflammatory factors wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Liao, Wei-Chih, Chen, Chih-Ta, Tsai, You-Shu, Wang, Xin-Ya, Chang, Yen-Tzu, Wu, Ming-Shiang, Chow, Lu-Ping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10242984/
https://www.ncbi.nlm.nih.gov/pubmed/37280516
http://dx.doi.org/10.1186/s12885-023-11009-8
_version_ 1785054334228103168
author Liao, Wei-Chih
Chen, Chih-Ta
Tsai, You-Shu
Wang, Xin-Ya
Chang, Yen-Tzu
Wu, Ming-Shiang
Chow, Lu-Ping
author_facet Liao, Wei-Chih
Chen, Chih-Ta
Tsai, You-Shu
Wang, Xin-Ya
Chang, Yen-Tzu
Wu, Ming-Shiang
Chow, Lu-Ping
author_sort Liao, Wei-Chih
collection PubMed
description BACKGROUND: Cancer cachexia, occurring in ~ 80% pancreatic cancer (PC) patients overall, is a paraneoplastic syndrome mediated by cancer-induced systemic inflammation and characterized by weight loss and skeletal muscle wasting. Identifying clinically relevant PC-derived pro-inflammatory factors with cachexigenic potential may provide novel insights and therapeutic strategies. METHODS: Pro-inflammatory factors with cachexigenic potential in PC were identified by bioinformatic analysis. The abilities of selected candidate factors in inducing skeletal muscle atrophy were investigated. Expression levels of candidate factors in tumors and sera was compared between PC patients with and without cachexia. Associations between serum levels of the candidates and weight loss were assessed in PC patients. RESULTS: S100A8, S100A9, and S100A8/A9 were identified and shown to induce C2C12 myotube atrophy. Tumors of PC patients with cachexia had markedly elevated expression of S100A8 (P = 0.003) and S100A9 (P < 0.001). PC patients with cachexia had significantly higher serum levels of S100A8, S100A9 and S100A8/A9. Serum levels of these factors positively correlated with percentage of weight loss [correlation coefficient: S100A8: 0.33 (P < 0.001); S100A9: 0.30 (P < 0.001); S100A8/A9: 0.24 (P = 0.004)] and independently predicted the occurrence of cachexia [adjusted odds ratio (95% confidence interval) per 1ng/ml increase: S100A8 1.11 (1.02–1.21), P = 0.014; S100A9 1.10 (1.04–1.16), P = 0.001; per 1 µg/ml increase: S100A8/A9 1.04 (1.01–1.06), P = 0.009]. CONCLUSIONS: Atrophic effects of S100A8, S100A9, and S100A8/A9 indicated them as potential pathogenic factors of PC-induced cachexia. In addition, the correlation with the degree of weight loss and prediction of cachexia in PC patients implicated their potential utility in the diagnosis of PC-induced cachexia. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-023-11009-8.
format Online
Article
Text
id pubmed-10242984
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-102429842023-06-07 S100A8, S100A9 and S100A8/A9 heterodimer as novel cachexigenic factors for pancreatic cancer-induced cachexia Liao, Wei-Chih Chen, Chih-Ta Tsai, You-Shu Wang, Xin-Ya Chang, Yen-Tzu Wu, Ming-Shiang Chow, Lu-Ping BMC Cancer Research BACKGROUND: Cancer cachexia, occurring in ~ 80% pancreatic cancer (PC) patients overall, is a paraneoplastic syndrome mediated by cancer-induced systemic inflammation and characterized by weight loss and skeletal muscle wasting. Identifying clinically relevant PC-derived pro-inflammatory factors with cachexigenic potential may provide novel insights and therapeutic strategies. METHODS: Pro-inflammatory factors with cachexigenic potential in PC were identified by bioinformatic analysis. The abilities of selected candidate factors in inducing skeletal muscle atrophy were investigated. Expression levels of candidate factors in tumors and sera was compared between PC patients with and without cachexia. Associations between serum levels of the candidates and weight loss were assessed in PC patients. RESULTS: S100A8, S100A9, and S100A8/A9 were identified and shown to induce C2C12 myotube atrophy. Tumors of PC patients with cachexia had markedly elevated expression of S100A8 (P = 0.003) and S100A9 (P < 0.001). PC patients with cachexia had significantly higher serum levels of S100A8, S100A9 and S100A8/A9. Serum levels of these factors positively correlated with percentage of weight loss [correlation coefficient: S100A8: 0.33 (P < 0.001); S100A9: 0.30 (P < 0.001); S100A8/A9: 0.24 (P = 0.004)] and independently predicted the occurrence of cachexia [adjusted odds ratio (95% confidence interval) per 1ng/ml increase: S100A8 1.11 (1.02–1.21), P = 0.014; S100A9 1.10 (1.04–1.16), P = 0.001; per 1 µg/ml increase: S100A8/A9 1.04 (1.01–1.06), P = 0.009]. CONCLUSIONS: Atrophic effects of S100A8, S100A9, and S100A8/A9 indicated them as potential pathogenic factors of PC-induced cachexia. In addition, the correlation with the degree of weight loss and prediction of cachexia in PC patients implicated their potential utility in the diagnosis of PC-induced cachexia. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-023-11009-8. BioMed Central 2023-06-06 /pmc/articles/PMC10242984/ /pubmed/37280516 http://dx.doi.org/10.1186/s12885-023-11009-8 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Liao, Wei-Chih
Chen, Chih-Ta
Tsai, You-Shu
Wang, Xin-Ya
Chang, Yen-Tzu
Wu, Ming-Shiang
Chow, Lu-Ping
S100A8, S100A9 and S100A8/A9 heterodimer as novel cachexigenic factors for pancreatic cancer-induced cachexia
title S100A8, S100A9 and S100A8/A9 heterodimer as novel cachexigenic factors for pancreatic cancer-induced cachexia
title_full S100A8, S100A9 and S100A8/A9 heterodimer as novel cachexigenic factors for pancreatic cancer-induced cachexia
title_fullStr S100A8, S100A9 and S100A8/A9 heterodimer as novel cachexigenic factors for pancreatic cancer-induced cachexia
title_full_unstemmed S100A8, S100A9 and S100A8/A9 heterodimer as novel cachexigenic factors for pancreatic cancer-induced cachexia
title_short S100A8, S100A9 and S100A8/A9 heterodimer as novel cachexigenic factors for pancreatic cancer-induced cachexia
title_sort s100a8, s100a9 and s100a8/a9 heterodimer as novel cachexigenic factors for pancreatic cancer-induced cachexia
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10242984/
https://www.ncbi.nlm.nih.gov/pubmed/37280516
http://dx.doi.org/10.1186/s12885-023-11009-8
work_keys_str_mv AT liaoweichih s100a8s100a9ands100a8a9heterodimerasnovelcachexigenicfactorsforpancreaticcancerinducedcachexia
AT chenchihta s100a8s100a9ands100a8a9heterodimerasnovelcachexigenicfactorsforpancreaticcancerinducedcachexia
AT tsaiyoushu s100a8s100a9ands100a8a9heterodimerasnovelcachexigenicfactorsforpancreaticcancerinducedcachexia
AT wangxinya s100a8s100a9ands100a8a9heterodimerasnovelcachexigenicfactorsforpancreaticcancerinducedcachexia
AT changyentzu s100a8s100a9ands100a8a9heterodimerasnovelcachexigenicfactorsforpancreaticcancerinducedcachexia
AT wumingshiang s100a8s100a9ands100a8a9heterodimerasnovelcachexigenicfactorsforpancreaticcancerinducedcachexia
AT chowluping s100a8s100a9ands100a8a9heterodimerasnovelcachexigenicfactorsforpancreaticcancerinducedcachexia